. 2016 Dec 22;31(4):1449–1460. doi: 10.1096/fj.201600927R

TABLE 3.

Clinical characteristics of NW, OW, OB, OW/T2DM, and OB/T2DM, subjects in the cross-sectional study

Charateristic	NW, n = 156	OW, n = 71	OB, n = 78	OW/T2DM, n = 40	OB/T2DM, n = 36	P^a
Female/male	100/56	46/25	39/39	18/22	20/16	NS
Age (yr)	43 ± 11.2	46.2 ± 7.4	38.3 ± 11.9*^,^‡	56.9 ± 7.3*^,^‡	55.8 ± 8.9*,^§	<0.01
BMI (kg/m²)	20.6 ± 0.9	26 ± 0.7*	30.8 ± 3.4*^,^‡	26 ± 0.6*^,^‡	30.4 ± 3.8*	<0.01
SBP (mmHg)	113.9 ± 10.8	115.8 ± 11.5	126.2 ± 17.8*^,^‡	135.1 ± 18.6*^,^‡	141.4 ± 24.8*^,^§	<0.01
DBP (mmHg)	71.2 ± 8	75.2 ± 7.8*	78.3 ± 11.6*	78.6 ± 12.4*	86.4 ± 14.4*^,^§	<0.01
TC (mM)	4.2 ± 0.6	4.3 ± 0.5	4.7 ± 0.8*^,^‡	5.4 ± 0.9*^,^‡	5.5 ± 1*^,^§	<0.01
TG (mM)	0.8 ± 0.3	1 ± 0.3*	1.6 ± 1.3*^,^‡	2.4 ± 1.5*^,^‡	2.2 ± 1.3*^,^§	<0.01
HDL-c (mM)	1.6 ± 0.3	1.4 ± 0.3*	1.2 ± 0.3*^,^‡	1.3 ± 0.2*^,^‡	1.3 ± 0.3*	<0.01
LDL-c (mM)	2.4 ± 0.5	2.6 ± 0.4*	2.9 ± 0.6*^,^‡	3.3 ± 0.8*^,^‡	3.3 ± 0.8*	<0.01
FPG (mM)	5 ± 0.4	5.1 ± 0.4*	5.2 ± 0.5*	8.2 ± 3*^,^‡	7.8 ± 2.1*^,^§	<0.01
2hPG (mM)	5.6 ± 1.1	5.8 ± 1.1	6.6 ± 1.5*^,^‡	15.1 ± 4.6*^,^‡	14.2 ± 4*^,^§	<0.01
HbA1c (%)	5.3 ± 0.3	5.4 ± 0.3	5.4 ± 0.4	7.2 ± 1.5*^,^‡	7 ± 1.1*^,^§	<0.01
FIns (μU/ml)	6 ± 2.7	8.4 ± 3.7*	14.8 ± 14.5*^,^‡	9.7 ± 5*	18.1 ± 25.1*	<0.01
2hIns (μU/ml)	31.7 ± 20.2	36.2 ± 23.8	88.3 ± 73.4*^,^‡	64.2 ± 47.4*^,^‡	87.3 ± 66*	<0.01
HOMA-IR	1.3 ± 0.6	1.9 ± 0.9*	3.5 ± 4.1*^,^‡	3.4 ± 1.9*^,^‡	6.5 ± 10.6*^,^§	<0.01
Matsuda ISI	242.5 ± 161.3	178.1 ± 95.4*	108.9 ± 76.9*^,^‡	71.3 ± 27.3*^,^‡	52.3 ± 23.3*^,^§	<0.01

NS, not significant. ^aValues were calculated by Kruskal-Wallis H test. Data are means ± sd. *P < 0.01 vs. NW; ^‡P < 0.01 vs. OW; ^§P < 0.01 vs. OB by the Mann-Whitney U test.